Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00010387 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00010387: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00010387 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00010387, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Determine the response rate and 1-year event-free survival in patients with severe autoimmune hematologic disease treated with high-dose cyclophosphamide.
Interventions
- DRUG cyclophosphamide
- DRUG filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 1999-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00010387
The ClinicalTrials.gov registry entry for NCT00010387 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cyclophosphamide is the first listed.
NCT00010387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00010387 about?
NCT00010387 is a clinical study titled "Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease". OBJECTIVES: I. Determine the response rate and 1-year event-free survival in patients with severe autoimmune hematologic disease treated with high-dose cyclophosphamide.
What is the current status of trial NCT00010387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 1999-03.
What interventions are being tested in trial NCT00010387?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (DRUG).
Who is sponsoring clinical trial NCT00010387?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.